Results · Apr-Jun 2026 · filed 11 Aug 2026
Biofil Chemicals & Pharmaceuticals Q1 FY27 results
Sales grew 92% to ₹12.4 crore from ₹6.4 crore in Apr-Jun 2025.
Operating profit grew 2324% to ₹0.14 crore, an operating margin of 1.1% (up 1.0 points from a year ago).
Net profit fell 95% to ₹0.11 crore from ₹2.4 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +63%, net profit −49%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 12.4 | 6.4 | +92% |
| Operating profit (EBITDA) | 0.1 | 0.0 | +2324% |
| Operating margin | 1.1% | 0.1% | +1.0 pts |
| Net profit | 0.1 | 2.4 | −95% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Change in Management
- 11 Aug 2026Un-Audited Financial Results For The Quarter Ended 30Th June 2026
- 11 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday 11Th August, 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requi
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.